CYCLOBENZAPRINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777	NDA AUTHORIZED GENERIC	Teva Pharmaceuticals USA, Inc.	0093-1920-06	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0093-1920-06)	2019-03-04
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777	NDA AUTHORIZED GENERIC	Teva Pharmaceuticals USA, Inc.	0093-1921-06	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0093-1921-06)	2019-03-04
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777	NDA AUTHORIZED GENERIC	Amneal Pharmaceuticals of New York LLC	0115-1436-13	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1436-13)	2019-03-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 28, 2025

Introduction

Cyclobenzaprine Hydrochloride, a widely prescribed muscle relaxant, primarily treats muscle spasms associated with acute musculoskeletal conditions. Originally developed in the 1960s, it has become a staple in clinical settings, especially for short-term management of muscle spasm pain. Given its widespread use, supply chain stability and reliable sourcing are critical for pharmaceutical manufacturers, distributors, and healthcare providers. This article explores the landscape of suppliers for Cyclobenzaprine Hydrochloride, emphasizing manufacturing sources, key players, geographic distribution, regulatory considerations, and market trends.

Manufacturing Landscape of Cyclobenzaprine Hydrochloride

Cyclobenzaprine Hydrochloride is produced through complex chemical synthesis involving multiple stages, including the formation of the central pyrrolidine ring structure. The synthesis process necessitates specialized chemical expertise, high-quality raw materials, and stringent quality control to meet regulatory standards such as Good Manufacturing Practice (GMP).

The manufacturing process comprises two primary components:

Active Pharmaceutical Ingredient (API) Production: Companies synthesize cyclobenzaprine base, which is subsequently purified and converted into the hydrochloride salt.
Finished Dosage Form Production: The API is formulated into tablets, capsules, or other dosage forms by contract or in-house manufacturers.

The global supply chain for cyclobenzaprine API is primarily concentrated in countries with robust pharmaceutical manufacturing sectors, notably India, China, and the United States.

Leading Suppliers of Cyclobenzaprine Hydrochloride

1. Indian Pharmaceutical Companies

India’s pharmaceutical industry ranks among the world's largest API producers, benefiting from cost advantages, a skilled workforce, and established GMP compliance.

Sun Pharmaceutical Industries Ltd.
As one of India’s largest drug manufacturers, Sun Pharma produces a range of APIs, including cyclobenzaprine hydrochloride, catering to domestic and international markets. Its extensive manufacturing infrastructure ensures high-quality API supply.
Lupin Limited
Lupin is another major player, with a significant API manufacturing division. The company emphasizes quality assurance and compliance with global standards, making its cyclobenzaprine APIs a preferred choice for several generic formulations.
Aurobindo Pharma
Aurobindo’s API manufacturing division spans multiple therapeutic areas, including central nervous system drugs. Its cyclobenzaprine API production meets stringent international regulatory requirements.

2. Chinese API Manufacturers

China’s API sector plays an integral role in global supply, offering competitive pricing and extensive capacity.

Hubei Hongjing Pharmaceutical Co., Ltd.
Specializing in semi-synthetic APIs, this manufacturer supplies cyclobenzaprine hydrochloride to major pharmaceutical firms worldwide.
Yangtze River Pharmaceutical Group
Known for its comprehensive portfolio, the company provides high-quality APIs with a focus on domestic and export markets.
Shenzhen Neptunus Biotech Co., Ltd.
An emerging player in API synthesis, including cyclobenzaprine hydrochloride, with increasing regulatory approvals.

3. U.S. and European API Suppliers

While less prevalent than Asian manufacturers, US and European API producers tend to serve high-end or specialized markets requiring rigorous quality standards.

Catalent Pharma Solutions (U.S.)
As a leading contract development and manufacturing organization (CDMO), Catalent offers custom API manufacturing and has capabilities for high-quality cyclobenzaprine production.
EU-based Companies
Several European API manufacturers supply cyclobenzaprine hydrochloride to pharmaceutical companies that prioritize European GMP standards, especially for markets within the EU.

4. Contract Manufacturing & Raw Material Suppliers

Many pharmaceutical companies engage contract manufacturing organizations (CMOs) to produce cyclobenzaprine APIs, relying on large-scale chemical suppliers for raw materials such as starting chemicals and intermediates.

5. Patent and Regulatory Considerations

Cyclobenzaprine Hydrochloride’s patent landscape has evolved considerably over decades. While patents have largely expired, ensuring the compliance and regulatory approval of suppliers remains vital, especially regarding bioequivalence, purity, and manufacturing process validation.

Market Dynamics and Supply Chain Considerations

Global Supply Chain Challenges

Regulatory Compliance: Suppliers must meet rigorous standards set by agencies like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and CDSCO (India’s Central Drugs Standard Control Organization). Non-compliance risks supply disruptions.
Raw Material Availability: Fluctuations in raw material prices and availability, owing to geopolitical issues or environmental regulations, can impact supply.
Quality Control: Stringent quality assurance protocols ensure API consistency, crucial for therapeutic efficacy and safety.

Impact of Geopolitical and COVID-19 Pandemic Factors

The pandemic exposed vulnerabilities in global supply chains, compelling companies to diversify sourcing and increase inventory buffers. Indian and Chinese suppliers have faced scrutiny but remain dominant due to scale and cost advantages.

Emerging Trends

Supply Chain Localization: Some companies are contemplating regional sourcing to mitigate risks.
Vertical Integration: Larger pharma firms are exploring in-house API production to secure supply and control quality.
Sustainability Initiatives: Increasing emphasis on environmentally friendly manufacturing practices influence supplier selection.

Regulatory and Quality Assurance

Suppliers must adhere to GMP standards and provide comprehensive documentation, including batch records, stability data, and purity profiles. Regulatory approvals, such as FDA registration or manufacturing certifications from international bodies, are often prerequisites for API licensing and supply agreements.

Conclusion

The landscape of cyclobenzaprine hydrochloride suppliers reflects a diverse, international ecosystem primarily dominated by Indian and Chinese pharmaceutical manufacturers. These suppliers offer cost-effective, high-quality APIs that adhere to rigorous global standards, ensuring consistent supply for the global market. As supply chain resilience becomes an increasing concern, stakeholders are focusing on supplier diversification, quality assurance, and compliance with evolving regulatory demands.

Key Takeaways

Major suppliers are concentrated in India, China, and specialized markets within the U.S. and Europe.
Regulatory compliance and quality assurance are critical factors in supplier selection.
The supply chain is impacted by geopolitical, regulatory, and pandemic-related factors, necessitating proactive risk management.
Emerging trends include localization of supply sources and increased focus on sustainability.
Contract manufacturing organizations (CMOs) play a vital role in expanding supply capacity and ensuring quality.

FAQs

1. Are there any exclusively licensed manufacturers for Cyclobenzaprine Hydrochloride?
Most cyclobenzaprine APIs are produced by major pharmaceutical companies with GMP certification; however, patent expirations have led to multiple generics, reducing the prevalence of exclusive licenses.

2. How can companies verify the quality compliance of API suppliers?
By reviewing certifications such as GMP compliance, requesting third-party laboratory analyses, reviewing audit reports, and examining regulatory approvals from relevant agencies.

3. What are the risks associated with relying on suppliers from specific countries?
Risks include geopolitical instability, regulatory changes, supply disruptions, and quality variances. Diversifying sources mitigates these risks.

4. Is there a significant difference in the quality of Cyclobenzaprine Hydrochloride APIs from Indian vs. Chinese manufacturers?
Both countries produce high-quality APIs meeting international standards, provided the manufacturer adheres to GMP and regulatory requirements.

5. How does patent expiration affect the supply market for Cyclobenzaprine Hydrochloride?
Patent expiration increases the number of manufacturers producing generics, expanding the supply chain and often reducing costs, but also emphasizes the importance of regulatory compliance to ensure quality.

Sources

[1] U.S. Food and Drug Administration (FDA). “Guidance for Industry - Manufacturing, Processing, or Storage of Injectable Drugs,” FDA.gov.
[2] Indian pharmaceutics industry reports, Pharmaprojects Database.
[3] Chinese pharmaceutical industry publications, China Pharmaceutical Industry Yearbook.
[4] European Medicines Agency (EMA). “Good Manufacturing Practice (GMP) Guidelines,” EMA.europa.eu.
[5] Market analysis reports from IQVIA and EvaluatePharma.

Suppliers and packagers for generic pharmaceutical drug: CYCLOBENZAPRINE HYDROCHLORIDE